• 5 min read
• Published on 25 July 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Hypertension Therapy Innovators
Let’s be honest, for the longest time, the world of cardiovascular medicine has felt a bit, well, sleepy. While other fields were chasing gene therapies and bespoke cancer treatments, the approach to high blood pressure seemed stuck in the past. The drugs worked, mostly, but genuine innovation felt like a distant memory. It was a bit like still using a dial-up modem. It gets you online, but you wouldn’t call it cutting edge.
Then, AstraZeneca decided to wake everyone up. Their recent success with a drug called baxdrostat isn't just another pill to add to the cabinet. To me, it feels like the first truly new idea in hypertension treatment we’ve seen in decades. And when a new idea works, investors should pay attention.
View the full Basket:Hypertension Therapy Innovators
First, let's grasp the sheer size of this market. We're talking about more than a billion people worldwide with high blood pressure. A billion. It’s the silent accomplice to heart attacks, strokes, and kidney failure. Yet, for all the existing medications, a stubborn 10 to 15 percent of patients have what’s called "treatment-resistant" hypertension. These are the people taking three or more different pills a day and still seeing dangerously high readings.
For them, the current pharmacy has essentially thrown its hands up. This isn't just a medical challenge, it's a colossal commercial opportunity hiding in plain sight. It’s a market full of customers who are desperate for something, anything, that actually works.
View the full Basket:Hypertension Therapy Innovators
So, what has AstraZeneca done that’s so clever? Instead of tinkering with the same old mechanical pathways that other drugs use, baxdrostat blocks the production of a hormone called aldosterone. In simple terms, aldosterone tells your body to hang onto salt and water, which in turn pushes your blood pressure up. AstraZeneca’s drug simply tells it to stop.
The results from trials on those hard-to-treat patients were impressive. It’s not just about one company getting a drug over the line. It’s about proving that a completely new approach can succeed. This validation sends a powerful signal across the entire industry, suggesting there are still treasure maps to be found in territories everyone thought were fully explored.
View the full Basket:Hypertension Therapy Innovators
When one giant validates a new path, others are quick to follow the scent. This single success could re-energise the entire cardiovascular space. Think of companies like Eli Lilly, already a powerhouse in metabolic diseases like diabetes and obesity, which often go hand in hand with hypertension. Or consider Novo Nordisk, the leader in diabetes care, whose research has already shown cardiovascular benefits.
Suddenly, their own innovative projects in this area might look a lot more promising to the market. This is where a broader investment theme emerges. The success of one drug could lift the boats of all the key players exploring novel treatments, creating a category of what you might call {{ $json.output.basketName }}. It’s a classic case of a rising tide, where renewed interest and research funding could benefit the whole sector.
Of course, this is the pharmaceutical world, and nothing is ever a sure bet. A promising drug can stumble at the final regulatory hurdle, and the market for blood pressure medication is notoriously crowded with cheap generics. Any new, expensive treatment has to prove it’s worth the money. But for the first time in a long while, there’s a palpable sense of momentum. It seems the old workhorse of medicine might just be learning a few new tricks after all.
View the full Basket:Hypertension Therapy Innovators
View the full Basket:Hypertension Therapy Innovators
View the full Basket:Hypertension Therapy Innovators
View the full Basket:Hypertension Therapy Innovators
View the full Basket:Hypertension Therapy Innovators
View the full Basket:Hypertension Therapy Innovators
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article